Diadema Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Diadema Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35,144	Closed	-$736K	–	188
2026 Q1	$736K	Buy	+35,144	New	+$791K	0.13%	97
2025 Q4	–	Sell	-9,189	Closed	-$302K	–	182
2025 Q3	$276K	Sell	9,189 -44,796	-83%	-$1.34M	0.07%	109
2025 Q2	$1.96M	Buy	+53,985	New	+$1.95M	0.6%	43

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Diadema Partners's RARE Position: Q2 2026 in Review

Diadema Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 35,144 shares — an estimated $736K sold.

Diadema Partners first reported a position in RARE in Q2 2025 and held it in 3 quarters. The position peaked at $1.96M in Q2 2025. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Diadema Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Diadema Partners sold 35,144 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $736K.
Diadema Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and held it in 3 quarters.
Diadema Partners's Ultragenyx Pharmaceutical position peaked at $1.96M in Q2 2025.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.